These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35770902)

  • 1. Spatially Patterned Neutralizing Icosahedral DNA Nanocage for Efficient SARS-CoV-2 Blocking.
    Zhang J; Xu Y; Huang Y; Sun M; Liu S; Wan S; Chen H; Yang C; Yang Y; Song Y
    J Am Chem Soc; 2022 Jul; 144(29):13146-13153. PubMed ID: 35770902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial- and Valence-Matched Neutralizing DNA Nanostructure Blocks Wild-Type SARS-CoV-2 and Omicron Variant Infection.
    Wan S; Liu S; Sun M; Zhang J; Wei X; Song T; Li Y; Liu X; Chen H; Yang CJ; Song Y
    ACS Nano; 2022 Sep; 16(9):15310-15317. PubMed ID: 36073793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape.
    Sun M; Liu S; Song T; Chen F; Zhang J; Huang JA; Wan S; Lu Y; Chen H; Tan W; Song Y; Yang C
    J Am Chem Soc; 2021 Dec; 143(51):21541-21548. PubMed ID: 34855379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein.
    Zhang S; Go EP; Ding H; Anang S; Kappes JC; Desaire H; Sodroski JG
    J Virol; 2022 Feb; 96(3):e0162621. PubMed ID: 34817202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
    Barnes CO; Jette CA; Abernathy ME; Dam KA; Esswein SR; Gristick HB; Malyutin AG; Sharaf NG; Huey-Tubman KE; Lee YE; Robbiani DF; Nussenzweig MC; West AP; Bjorkman PJ
    Nature; 2020 Dec; 588(7839):682-687. PubMed ID: 33045718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.
    Li R; Mor M; Ma B; Clark AE; Alter J; Werbner M; Lee JC; Leibel SL; Carlin AF; Dessau M; Gal-Tanamy M; Croker BA; Xiang Y; Freund NT
    Commun Biol; 2022 Aug; 5(1):789. PubMed ID: 35931732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants.
    Du W; Jiang P; Li Q; Wen H; Zheng M; Zhang J; Guo Y; Yang J; Feng W; Ye S; Kamara S; Jiang P; Chen J; Li W; Zhu S; Zhang L
    Microbiol Spectr; 2023 Feb; 11(1):e0356222. PubMed ID: 36511681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potently neutralizing and protective human antibodies against SARS-CoV-2.
    Zost SJ; Gilchuk P; Case JB; Binshtein E; Chen RE; Nkolola JP; Schäfer A; Reidy JX; Trivette A; Nargi RS; Sutton RE; Suryadevara N; Martinez DR; Williamson LE; Chen EC; Jones T; Day S; Myers L; Hassan AO; Kafai NM; Winkler ES; Fox JM; Shrihari S; Mueller BK; Meiler J; Chandrashekar A; Mercado NB; Steinhardt JJ; Ren K; Loo YM; Kallewaard NL; McCune BT; Keeler SP; Holtzman MJ; Barouch DH; Gralinski LE; Baric RS; Thackray LB; Diamond MS; Carnahan RH; Crowe JE
    Nature; 2020 Aug; 584(7821):443-449. PubMed ID: 32668443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
    Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
    Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
    Carnell GW; Ciazynska KA; Wells DA; Xiong X; Aguinam ET; McLaughlin SH; Mallery D; Ebrahimi S; Ceron-Gutierrez L; Asbach B; Einhauser S; Wagner R; James LC; Doffinger R; Heeney JL; Briggs JAG
    J Virol; 2021 Jul; 95(15):e0020321. PubMed ID: 33963055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.
    Zheng Y; Larragoite ET; Williams ESCP; Lama J; Cisneros I; Delgado JC; Slev P; Rychert J; Innis EA; Coiras M; Rondina MT; Spivak AM; Planelles V
    Virol J; 2021 Jan; 18(1):1. PubMed ID: 33397387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
    Mondal T; Shivange G; Habieb A; Tushir-Singh J
    Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.